Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia—Reply

ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia—Reply Letters COMMENT & RESPONSE a study by Thomas et al found the benefits to wane by month 8 of the treatment. An important difference between the In Reply Pahwa and Hauser raise legitimate concerns based on AMANDYSK trial and the study by Thomas et al is the differ- my Editorial. In the EASE LID study, amantadine extended re- ence in the characteristic of dyskinesia. While the former ran- lease was found to demonstrate efficacy in a randomized domized clinical trial enrolled peak-dose LID, the latter had a double-blind placebo-controlled design for treatment of broader cohort of peak and diphasic dyskinesia. Notably, the levodopa-induced dyskinesias (LID) in Parkinson disease (PD). mean (SD) duration of amantadine response was 3.4 (4.1) years Pahwa and Hauser have expressed concerns over aspects (sufficiently long) for the 56 participants in the AMANDYSK of amantadine therapy that I discussed in the Editorial trial. In another washout study by Wolf et al, 32 patients re- following the EASE LID study and I would like to address each sponding to amantadine for a mean (SD) of 4.8 (2.9) years were of their comments. enrolled. A significant worsening of LID was observed in the Pahwa and Hauser are concerned http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia—Reply

JAMA Neurology , Volume 74 (12) – Dec 6, 2017

ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia—Reply

Abstract

Letters COMMENT & RESPONSE a study by Thomas et al found the benefits to wane by month 8 of the treatment. An important difference between the In Reply Pahwa and Hauser raise legitimate concerns based on AMANDYSK trial and the study by Thomas et al is the differ- my Editorial. In the EASE LID study, amantadine extended re- ence in the characteristic of dyskinesia. While the former ran- lease was found to demonstrate efficacy in a randomized domized clinical trial enrolled peak-dose LID,...
Loading next page...
 
/lp/american-medical-association/ads-5102-amantadine-extended-release-for-levodopa-induced-dyskinesia-56EVL63DYH
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2017.3211
Publisher site
See Article on Publisher Site

Abstract

Letters COMMENT & RESPONSE a study by Thomas et al found the benefits to wane by month 8 of the treatment. An important difference between the In Reply Pahwa and Hauser raise legitimate concerns based on AMANDYSK trial and the study by Thomas et al is the differ- my Editorial. In the EASE LID study, amantadine extended re- ence in the characteristic of dyskinesia. While the former ran- lease was found to demonstrate efficacy in a randomized domized clinical trial enrolled peak-dose LID, the latter had a double-blind placebo-controlled design for treatment of broader cohort of peak and diphasic dyskinesia. Notably, the levodopa-induced dyskinesias (LID) in Parkinson disease (PD). mean (SD) duration of amantadine response was 3.4 (4.1) years Pahwa and Hauser have expressed concerns over aspects (sufficiently long) for the 56 participants in the AMANDYSK of amantadine therapy that I discussed in the Editorial trial. In another washout study by Wolf et al, 32 patients re- following the EASE LID study and I would like to address each sponding to amantadine for a mean (SD) of 4.8 (2.9) years were of their comments. enrolled. A significant worsening of LID was observed in the Pahwa and Hauser are concerned

Journal

JAMA NeurologyAmerican Medical Association

Published: Dec 6, 2017

References